Evidence map›Paper›PMID 35757735›Full record

ArticleFrontiers in immunology2022

Loss of Lipocalin 10 Exacerbates Diabetes-Induced Cardiomyopathy

Qianqian Li, Yutian Li, Wei Huang, Xiaohong Wang, Zhenling Liu, Jing Chen, Yanbo Fan, Tianqing Peng, Sakthivel Sadayappan, Yigang Wang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Qianqian LiDivision of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, United States.
Yutian LiDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Wei HuangDepartment of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Xiaohong WangDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Zhenling LiuDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Jing ChenDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Yanbo FanDepartment of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Tianqing PengThe Centre for Critical Illness Research, Lawson Health Research Institute, London, ON, Canada.
Sakthivel SadayappanDivision of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Yigang WangDepartment of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Guo-Chang FanDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
University of Cincinnati Medical Center · USLawson Health Research Institute · CA

Funding

Fast myosin binding protein-C and cardiac contractility in heart failureR01HL105826 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2011 to 2025
$4.5M
Lcn10 in Sepsis-Induced Vascular Leakage and Heart FailureR01HL160811 · NHLBI · UNIVERSITY OF CINCINNATI · PI FAN, GUO-CHANG · 2022 to 2025
$2.7M
The role of TFEB in aortic aneurysmsR01HL145176 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, YANBO · 2019 to 2022
$2.2M
Transcription Factor-EB and Postischemic AngiogenesisR01HL138094 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, YANBO · 2017 to 2021
$2.2M
Slow myosin binding protein-C in skeletal muscle physiologyR01AR078001 · NIAMS · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2020 to 2023
$1.8M
IGF-2R is a new therapeutic target for cardiac ischemia-reperfusion injuryR01HL143490 · NHLBI · UNIVERSITY OF CINCINNATI · PI WANG, YIGANG · 2019 to 2022
$1.6M
Molecular mechanism of hypertrophic cardiomyopathy in populations of South Asian descendantsR01HL130356 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2016 to 2019
$1.6M
Tsg101 and endosomes in cardiac surgery-induced injuryR01GM126061 · NIGMS · UNIVERSITY OF CINCINNATI · PI FAN, GUO-CHANG · 2018 to 2021
$1.2M
Roles of Sectm1a in macrophages and cardiac function during sepsisR01GM132149 · NIGMS · UNIVERSITY OF CINCINNATI · PI FAN, GUO-CHANG · 2019 to 2022
$1.2M
NHLBI NIH HHS R01 HL105826NHLBI NIH HHS R01 HL130356NHLBI NIH HHS R01 HL138094NHLBI NIH HHS R01 HL143490NHLBI NIH HHS R01 HL145176NHLBI NIH HHS R01 HL160811NIAMS NIH HHS R01 AR078001NIGMS NIH HHS R01 GM126061NIGMS NIH HHS R01 GM132149
6 · The paper itself

Abstract

Metabolic disorders (i.e., hyperglycemia, hyperlipidemia, and hyperinsulinemia) cause increased secretion of inflammatory cytokines/chemokines, leading to gradual loss of cardiac resident macrophage population and increased accumulation of inflammatory monocytes/macrophages in the heart. Such self-perpetuating effect may contribute to the development of cardiomyopathy during diabetes. Recent meta-analysis data reveal that lipocalin 10 (Lcn10) is significantly downregulated in cardiac tissue of patients with heart failure but is increased in the blood of septic patients. However, the functional role of Lcn10 in cardiac inflammation triggered by metabolic disorders has never been investigated. In this study, we demonstrate that the expression of Lcn10 in macrophages was significantly decreased under multiple metabolic stress conditions. Furthermore, Lcn10-null macrophages exhibited pro-inflammatory phenotype in response to inflammation stimuli. Next, using a global Lcn10-knockout (KO) mouse model to induce type-2 diabetes (T2D), we observed that loss of Lcn10 promoted more pro-inflammatory macrophage infiltration into the heart, compared to controls, leading to aggravated insulin resistance and impaired cardiac function. Similarly, adoptive transfer of Lcn10-KO bone marrow cells into X-ray irradiated mice displayed higher ratio of pro-/anti-inflammatory macrophages in the heart and worsened cardiac function than those mice received wild-type (WT) bone marrows upon T2D conditions. Mechanistically, RNA-sequencing analysis showed that Nr4a1, a nuclear receptor known to have potent anti-inflammatory effects, is involved in Lcn10-mediated macrophage activation. Indeed, we found that nuclear translocation of Nr4a1 was disrupted in Lcn10-KO macrophages upon stimulation with LPS + IFNγ. Accordingly, treatment with Cytosporone B (CsnB), an agonist of Nr4a1, attenuated the pro-inflammatory response in Lcn10-null macrophages and partially improved cardiac function in Lcn10-KO diabetic mice. Together, these findings indicate that loss of Lcn10 skews macrophage polarization to pro-inflammatory phenotype and aggravates cardiac dysfunction during type-2 diabetes through the disruption of Nr4a1-mediated anti-inflammatory signaling pathway in macrophages. Therefore, reduction of Lcn10 expression observed in diabetic macrophages may be responsible for the pathogenesis of diabetes-induced cardiac dysfunction. It suggests that Lcn10 might be a potential therapeutic factor for diabetic heart failure.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Heart FailureLipocalinsAnimalsHumansInflammationMacrophagesMiceMice, KnockoutNuclear Receptor Subfamily 4, Group A, Member 1LCN10 protein, humanLipocalinsNR4A1 protein, humanNr4a1 protein, mouseNuclear Receptor Subfamily 4, Group A, Member 1cardiac functiondiabeteslipocalinmacrophageNr4a1

Identifiers

PMID35757735
PMCPMC9226549
OpenAlexW4281995278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.